Mangifera indica Extracts as Novel PKM2 Inhibitors for Treatment of Triple Negative Breast Cancer

Biomed Res Int. 2021 May 26:2021:5514669. doi: 10.1155/2021/5514669. eCollection 2021.

Abstract

Pyruvate kinase (PK), a key enzyme that determines glycolytic activity, has been known to support the metabolic phenotype of tumor cells, and specific pyruvate kinase isoform M2 (PKM2) has been reported to fulfill divergent biosynthetic and energetic requirements of cancerous cells. PKM2 is overexpressed in several cancer types and is an emerging drug target for cancer during recent years. Therefore, this study was carried out to identify PKM2 inhibitors from natural products for cancer treatment. Based on the objectives of this study, firstly, plant extract library was established. In order to purify protein for the establishment of enzymatic assay system, pET-28a-HmPKM2 plasmid was transformed to E. coli BL21 (DE3) cells for protein expression and purification. After the validation of enzymatic assay system, plant extract library was screened for the identification of inhibitors of PKM2 protein. Out of 51 plant extracts screened, four extracts Mangifera indica (leaf, seed, and bark) and Bombex ceiba bark extracts were found to be inhibitors of PKM2. In the current study, M. indica (leaf, seed, and bark) extracts were further evaluated dose dependently against PKM2. These extracts showed different degrees of concentration-dependent inhibition against PKM2 at 90-360 μg/ml concentrations. We have also investigated the anticancer potential of these extracts against MDA-MB231 cells and generated dose-response curves for the evaluation of IC50 values. M. indica (bark and seed) extracts significantly halted the growth of MDA-MB231 cells with IC50 values of 108 μg/ml and 33 μg/ml, respectively. Literature-based phytochemical analysis of M. indica was carried out, and M. indica-derived 94 compounds were docked against three binding sites of PKM2 for the identification of PKM2 inhibitors. The results of in silico based screening have unveiled various PKM2 modulators; however, further studies are recommended to validate their PKM2 inhibitory potential via in vitro biochemical assay. The results of this study provide novel findings for possible mechanism of action of M. indica (bark and seed) extracts against TNBC via PKM2 inhibition suggesting that M. indica might be of therapeutic interest for the treatment of TNBC.

Publication types

  • Retracted Publication

MeSH terms

  • Antineoplastic Agents / pharmacology
  • Carrier Proteins / antagonists & inhibitors*
  • Cell Line, Tumor
  • Crystallography, X-Ray
  • Enzyme Inhibitors / pharmacology
  • Female
  • Humans
  • Inhibitory Concentration 50
  • Kinetics
  • Mangifera / metabolism*
  • Membrane Proteins / antagonists & inhibitors*
  • Plant Bark / metabolism
  • Plant Extracts / pharmacology*
  • Plant Leaves / metabolism
  • Plasmids / metabolism
  • Seeds / metabolism
  • Tetrazolium Salts
  • Thiazoles
  • Thyroid Hormone-Binding Proteins
  • Thyroid Hormones
  • Triple Negative Breast Neoplasms / drug therapy*
  • Triple Negative Breast Neoplasms / enzymology

Substances

  • Antineoplastic Agents
  • Carrier Proteins
  • Enzyme Inhibitors
  • Membrane Proteins
  • Plant Extracts
  • Tetrazolium Salts
  • Thiazoles
  • Thyroid Hormones
  • thiazolyl blue